RNK05047
RNK05047 is an investigational novel, small-molecule, chaperone-mediated protein degrader (CHAMP) targeting BRD4 (Bromodomain-Containing Protein 4) protein. RNK05047 accumulates in tumors relative to plasma and non-tumor tissues and induces degradation of BRD4 protein, but not related members of the Bromodomain and Extra-Terminal family (BET) protein family, BRD2 and BRD3, via the ubiquitin-proteasome system, thereby leading to downregulation of BRD4-regulated gene expression.
RNK08954
RNK08954 is an investigational novel, oral small-molecule, non-covalently inhibits KRAS (Kirsten rat sarcoma) G12D, selectively binds to KRAS G12D over other mutations and wild type and achieves high exposure in tumors for the treatment of advanced solid tumors with a specific KRAS Mutation.
Ranok Therapeutics
United States
303 Wyman Street, Suite 300
Waltham, MA 02451
China
Floor 4, Building 16
Hexiang Science and Technology Center
Qiantang District, Hangzhou 310020
0571-86630936
© 2023 Ranok Therapeutics Co. Ltd.